Search

Your search keyword '"Jürgen Tebbenjohanns"' showing total 4 results
Start Over Author "Jürgen Tebbenjohanns" Language english
4 results on '"Jürgen Tebbenjohanns"'

1. Impact of timing and combination of different BNT162b2 and ChAdOx1-S COVID-19 basic and booster vaccinations on humoral immunogenicity and reactogenicity in adults

Author

Simon Dedroogh, Sven Schmiedl, Petra A. Thürmann, Katharina Graf, Sebastian Appelbaum, Reinhard Koß, Christian Theis, Zewarudin Zia, Jürgen Tebbenjohanns, Serge C. Thal, and Michael Dedroogh

Subjects
Medicine, Science
Abstract

Abstract In this single-center observational study with 1,206 participants, we prospectively evaluated SARS-CoV-2-antibodies (anti-S RBD) and vaccine-related adverse drug reactions (ADR) after basic and booster immunization with BNT162b2- and ChAdOx1-S-vaccines in four vaccination protocols: Homologous BNT162b2-schedule with second vaccination at either three or six weeks, homologous ChAdOx1-S-vaccination or heterologous ChAdOx1-S/BNT162b2-schedule, each at 12 weeks. All participants received a BNT162b2 booster. Blood samples for anti-S RBD analysis were obtained multiple times over a period of four weeks to six months after basic vaccination, immediately before, and up to three months after booster vaccination. After basic vaccination, the homologous ChAdOx1-S-group showed the lowest anti-S RBD levels over six months, while the heterologous BNT162b2-ChAdOx1-S-group demonstrated the highest anti-S levels, but failed to reach level of significance compared with the homologous BNT162b2-groups. Antibody levels were higher after an extended vaccination interval with BNT162b2. A BNT162b2 booster increased anti-S-levels 11- to 91-fold in all groups, with the homologous ChAdOx1-S-cohort demonstrated the highest increase in antibody levels. No severe or serious ADR were observed. The findings suggest that a heterologous vaccination schedule or prolonged vaccination interval induces robust humoral immunogenicity with good tolerability. Extending the time to boost-immunization is key to both improving antibody induction and reducing ADR rate.

Published
2023
Full Text
View/download PDF

2. Outcomes of cryoballoon or radiofrequency ablation in symptomatic paroxysmal or persistent atrial fibrillation

Author

Dietrich Andresen, Jochen Senges, Andreas Metzner, Karl-Heinz Kuck, Julian Kyoung Ryul Chun, Ellen Hoffmann, Taoufik Ouarrak, Roland Richard Tilz, Johannes Brachmann, Georg Noelker, Li-Qun Wu, Jürgen Tebbenjohanns, Malte Kuniss, Arcadi García-Alberola, Uwe Dorwarth, Florian Straube, Andreas Franke, Christoph Stellbrink, and Karl Wegscheider

Subjects
Male, Reoperation, medicine.medical_specialty, Radiofrequency ablation, medicine.medical_treatment, Population, Paroxysmal, Operative Time, Catheter ablation, Lower risk, Cryoballoon, Radiation Dosage, Cryosurgery, Patient Readmission, law.invention, Cohort Studies, Postoperative Complications, law, Clinical Research, Recurrence, Physiology (medical), Internal medicine, Atrial Fibrillation, medicine, Clinical endpoint, Persistent, Humans, Prospective Studies, Adverse effect, education, Aged, Proportional Hazards Models, education.field_of_study, business.industry, Hazard ratio, Atrial fibrillation, Middle Aged, medicine.disease, Ablation for Atrial Fibrillation, Editor's Choice, surgical procedures, operative, Treatment Outcome, Radiofrequency, Cardiology, Catheter Ablation, Female, Cardiology and Cardiovascular Medicine, business
Abstract

Aims To evaluate the effectiveness and safety of cryoballoon ablation (CBA) compared with radiofrequency ablation (RFA) for symptomatic paroxysmal or drug-refractory persistent atrial fibrillation (AF). Methods and results Prospective cluster cohort study in experienced CBA and RFA centres. Primary endpoint was ‘atrial arrhythmia recurrence’, secondary endpoints were as follows: procedural results, safety, and clinical course. A total of 4189 patients were included: CBA 2329 (55.6%) and RFA 1860 (44.4%). Cryoballoon ablation population was younger, with fewer comorbidities. Procedure time was longer in the RFA group (P = 0.01). Radiation exposure was 2487 (CBA) and 1792 cGycm2 (RFA) (P Conclusions The primary endpoint did not differ between CBA and RFA. Cryoballoon ablation was completed rapidly; the radiation exposure was greater. Rehospitalization due to re-ablations and adverse events during follow-up were observed significantly less frequently after CBA than after RFA. Subgroup analysis suggested a lower risk of recurrence after CBA in paroxysmal AF. Trial Registration ClinicalTrials.gov (NCT01360008), https://clinicaltrials.gov/ct2/show/NCT01360008.

Published
2019

3. In-hospital mortality of patients with atrial arrhythmias: insights from the German-wide Helios hospital network of 161 502 patients and 34 025 arrhythmia-related procedures

Author

Gerhard Hindricks, Jan G.P. Tijssen, Ralf Kuhlen, Carsten Wunderlich, Anja Schade, Michael Wiedemann, Rene Andrie, Laura Ueberham, Dong-In Shin, Jürgen Tebbenjohanns, Ulrike Wetzel, Armin Sause, Andreas Bollmann, Sebastian König, Hans Neuser, Christopher Reithmann, Udo Zacharzowsky, Alexander Staudt, Melchior Seyfarth, Ekkehard Schuler, ACS - Amsterdam Cardiovascular Sciences, Cardiology, and ACS - Heart failure & arrhythmias

Subjects
Adult, Male, medicine.medical_specialty, Databases, Factual, medicine.medical_treatment, Catheter ablation, Comorbidity, 030204 cardiovascular system & hematology, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, Germany, Internal medicine, Atrial Fibrillation, medicine, Humans, International Statistical Classification of Diseases and Related Health Problems, Hospital Mortality, 030212 general & internal medicine, Aged, business.industry, Mortality rate, Age Factors, Atrial fibrillation, Odds ratio, Middle Aged, medicine.disease, Confidence interval, Treatment Outcome, Atrial Flutter, Catheter Ablation, Female, Emergency Service, Hospital, Cardiology and Cardiovascular Medicine, business, Hospitals, High-Volume, Atrial flutter
Abstract

Aims: Atrial fibrillation (AFib) and atrial flutter (AFlut) are common arrhythmias with increased use of invasive procedures. A steady re-evaluation of relevant safety endpoints is recommended and both quality management and pay-for-performance programs are evolving. Therefore, the aims of this study were (i) to investigate and report overall in-hospital mortality and mortality of invasive arrhythmia-related procedures and (ii) to identify mortality predictors in a German-wide hospital network. Methods and results: Administrative data provided by 78 Helios hospitals between 2010 and 2017 were examined using International Statistical Classification of Diseases and Related Health Problems- and Operations and Procedures-codes to identify patients with AFib or AFlut as main discharge diagnosis or secondary diagnosis combined with invasive arrhythmia-related interventions. In 161 502 patients, in-hospital mortality was 0.6% with a significant decrease from 0.75% to 0.5% (P

Published
2018

4. Increased open probability of single cardiac L-type calcium channels of patients with chronic atrial fibrillation: role of phosphatase 2A

Author

Arnd Schaefer, Frank Schröder, Axel Haverich, David Vogler, Gunnar Klein, Bernhard Schieffer, Jürgen Tebbenjohanns, and Helmut Drexler

Subjects
medicine.medical_specialty, Phosphatase 2A, business.industry, Internal medicine, P wave, Cardiology, Chronic atrial fibrillation, Medicine, L-type calcium channel, Cardiology and Cardiovascular Medicine, business, Open probability
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results